IT1274782B - Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130 - Google Patents
Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130Info
- Publication number
- IT1274782B IT1274782B ITRM940805A ITRM940805A IT1274782B IT 1274782 B IT1274782 B IT 1274782B IT RM940805 A ITRM940805 A IT RM940805A IT RM940805 A ITRM940805 A IT RM940805A IT 1274782 B IT1274782 B IT 1274782B
- Authority
- IT
- Italy
- Prior art keywords
- superantagonists
- site
- interleukin
- superagonists
- antagonists
- Prior art date
Links
- 229940088597 hormone Drugs 0.000 title abstract 4
- 239000005556 hormone Substances 0.000 title abstract 4
- 239000005557 antagonist Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 abstract 3
- 229940116886 human interleukin-6 Drugs 0.000 abstract 3
- 230000002483 superagonistic effect Effects 0.000 abstract 3
- 101000746370 Bos taurus Granulocyte colony-stimulating factor Proteins 0.000 abstract 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 abstract 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 abstract 2
- 102000003815 Interleukin-11 Human genes 0.000 abstract 2
- 108090000177 Interleukin-11 Proteins 0.000 abstract 2
- 102000004889 Interleukin-6 Human genes 0.000 abstract 2
- 108090001005 Interleukin-6 Proteins 0.000 abstract 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 abstract 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 abstract 2
- 102000004140 Oncostatin M Human genes 0.000 abstract 2
- 108090000630 Oncostatin M Proteins 0.000 abstract 2
- 230000003993 interaction Effects 0.000 abstract 2
- 229940074383 interleukin-11 Drugs 0.000 abstract 2
- 229940100601 interleukin-6 Drugs 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 201000000050 myeloid neoplasm Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/141—Interleukin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Obesity (AREA)
Priority Applications (16)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITRM940805A IT1274782B (it) | 1994-12-14 | 1994-12-14 | Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130 |
| DK95940409T DK0745094T3 (da) | 1994-12-14 | 1995-12-13 | Superagonister og antagonister mod human IL-6 og fremgangsmåder til deres udvælgelse |
| CA002177838A CA2177838A1 (en) | 1994-12-14 | 1995-12-13 | A methodology for selecting superagonists, antagonists and superantagonists of human interleukin-6 based on receptor complex three dimensional modelling |
| AU41871/96A AU702783B2 (en) | 1994-12-14 | 1995-12-13 | Superagonists and antagonists of H IL-6, and 3D modelling method for their selection |
| DE69529973T DE69529973T2 (de) | 1994-12-14 | 1995-12-13 | Superagonisten und Antagonisten von Humanen IL-6 und Methoden zu deren Selektion |
| CN95191575A CN1070866C (zh) | 1994-12-14 | 1995-12-13 | 用受体复合物三维模型筛选人白细胞介素-6的超激动剂、拮抗剂和超拮抗剂的方法 |
| JP51856296A JP3206919B2 (ja) | 1994-12-14 | 1995-12-13 | 受容体複合体三次元モデル化に基づくヒトインターロイキン−６のスーパーアゴニスト，アンタゴニストおよびスーパーアンタゴニストを選択する方法 |
| EP95940409A EP0745094B1 (en) | 1994-12-14 | 1995-12-13 | Superagonists and antagonists of human il-6, and method for their selection |
| ES95940409T ES2192585T3 (es) | 1994-12-14 | 1995-12-13 | Superagonistas y antagonistas de la h il-6 y metodo de modelado tridimensional para su seleccion. |
| HK98111981.1A HK1011032B (en) | 1994-12-14 | 1995-12-13 | Superagonists and antagonists of human il-6, and method for their selection |
| PT95940409T PT745094E (pt) | 1994-12-14 | 1995-12-13 | Superagonistas e antagonistas da il-6 humana e metodo para a sua seleccao |
| US08/693,182 US5849283A (en) | 1994-12-14 | 1995-12-13 | Human interleukin-6 receptor antagonists |
| PCT/IT1995/000216 WO1996018648A1 (en) | 1994-12-14 | 1995-12-13 | Superagonists and antagonists of h il-6, and 3d modelling method for their selection |
| AT95940409T ATE234864T1 (de) | 1994-12-14 | 1995-12-13 | Superagonisten und antagonisten von humanen il-6 und methoden zu deren selektion |
| US09/008,482 US5914106A (en) | 1994-12-14 | 1998-01-16 | Interleukin-6 receptor agonists |
| JP2001125516A JP3286310B2 (ja) | 1994-12-14 | 2001-04-24 | 受容体複合体三次元モデル化に基づくヒトインターロイキン−６のアンタゴニストおよびスーパーアンタゴニストを選択する方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITRM940805A IT1274782B (it) | 1994-12-14 | 1994-12-14 | Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| ITRM940805A0 ITRM940805A0 (it) | 1994-12-14 |
| ITRM940805A1 ITRM940805A1 (it) | 1996-06-14 |
| IT1274782B true IT1274782B (it) | 1997-07-24 |
Family
ID=11402859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ITRM940805A IT1274782B (it) | 1994-12-14 | 1994-12-14 | Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US5849283A (it) |
| EP (1) | EP0745094B1 (it) |
| JP (2) | JP3206919B2 (it) |
| CN (1) | CN1070866C (it) |
| AT (1) | ATE234864T1 (it) |
| AU (1) | AU702783B2 (it) |
| CA (1) | CA2177838A1 (it) |
| DE (1) | DE69529973T2 (it) |
| DK (1) | DK0745094T3 (it) |
| ES (1) | ES2192585T3 (it) |
| IT (1) | IT1274782B (it) |
| PT (1) | PT745094E (it) |
| WO (1) | WO1996018648A1 (it) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997016202A1 (en) * | 1995-10-27 | 1997-05-09 | Amrad Operations Pty. Ltd. | Cytokines and their use in treatment and/or prophylaxis of breast cancer |
| CA2237114A1 (en) * | 1995-11-07 | 1997-05-15 | Kaneka Corporation | Autoantigens |
| IT1285790B1 (it) | 1996-09-24 | 1998-06-24 | Angeletti P Ist Richerche Bio | Adenovirus difettivi ricombinanti che codificano per mutanti di interleuchina 6 umana (hil-6) con attivita' antagonista o |
| AUPO439396A0 (en) | 1996-12-24 | 1997-01-23 | Walter And Eliza Hall Institute Of Medical Research, The | A method of treatment and prophylaxis |
| GB9702944D0 (en) * | 1997-02-13 | 1997-04-02 | Univ Manchester | Reducing fibrosis |
| ES2382488T3 (es) | 1997-03-21 | 2012-06-08 | Chugai Seiyaku Kabushiki Kaisha | Un agente preventivo o terapéutico para enfermedades mediadas por células t sensibilizadas que comprende un antagonista de il-6 como ingrediente activo |
| CA2237915A1 (en) * | 1998-05-19 | 1999-11-19 | Stephen Shaughnessy | Osteoporosis treatment |
| JP2002519387A (ja) | 1998-07-06 | 2002-07-02 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 体外受精のための組成物および方法 |
| JP4799516B2 (ja) * | 1998-08-24 | 2011-10-26 | 中外製薬株式会社 | Ｉｌ−６アンタゴニストを有効成分として含有する膵炎の予防又は治療剤 |
| JP4711507B2 (ja) | 1998-08-24 | 2011-06-29 | 中外製薬株式会社 | Ｉｌ−６アンタゴニストを有効成分として含有する膵炎の予防又は治療剤 |
| US6541244B1 (en) * | 1999-06-07 | 2003-04-01 | Cedars-Sinai Medical Center | Suppressor of cytokine signaling (SOCS)-3 promoter and methods for its use in genetic therapy in humans |
| AU7078200A (en) | 1999-08-27 | 2001-03-26 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Polypeptides, comprising il-6 ligand-binding receptor domains and related nucleic acids, antibodies, compositions, and methods of use |
| UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
| US7247618B2 (en) * | 2001-04-30 | 2007-07-24 | Tripathi Rajavashisth | Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling |
| BRPI0214168B8 (pt) * | 2001-11-14 | 2021-05-25 | Centocor Inc | anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos |
| EP2002827A2 (en) | 2001-12-05 | 2008-12-17 | The Baylor College Of Medicine | Methods and compositions for control of bone formation via modulation of sympathetic tone |
| AU2004212843B2 (en) | 2003-02-24 | 2009-06-25 | Chugai Seiyaku Kabushiki Kaisha | Remedy for spinal injury containing interleukin-6 antagonist |
| GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| US20070134242A1 (en) | 2003-10-17 | 2007-06-14 | Chugai Seiyaku Kabushiki Kaisha | Mesothelioma therapeutic agent |
| US20050100550A1 (en) * | 2003-11-10 | 2005-05-12 | Mohit Trikha | Anti-angiogenic uses of IL-6 antagonists |
| AR048210A1 (es) | 2003-12-19 | 2006-04-12 | Chugai Pharmaceutical Co Ltd | Un agente preventivo para la vasculitis. |
| JO3058B1 (ar) | 2005-04-29 | 2017-03-15 | Applied Molecular Evolution Inc | الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها |
| AR061400A1 (es) | 2005-10-14 | 2008-08-27 | Chugai Kabushiki Kaisha | Agentes para suprimir el dano a los islotes transplantados despues del transplante de islotes |
| JP5191235B2 (ja) | 2005-10-21 | 2013-05-08 | 中外製薬株式会社 | 心疾患治療剤 |
| AR057582A1 (es) | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
| KR20080084818A (ko) | 2005-11-25 | 2008-09-19 | 각고호우징 게이오기주크 | 전립선암 치료제 |
| AU2007208678B2 (en) | 2006-01-27 | 2013-01-10 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agents for diseases involving choroidal neovascularization |
| CA2648644C (en) | 2006-04-07 | 2016-01-05 | Osaka University | Muscle regeneration promoter |
| BRPI0806812B8 (pt) | 2007-01-23 | 2021-09-14 | Chugai Pharmaceutical Co Ltd | Agente para suprimir reação de rejeição crônica e uso de um inibidor de il-6 |
| CN104906581A (zh) | 2008-06-05 | 2015-09-16 | 国立研究开发法人国立癌症研究中心 | 神经浸润抑制剂 |
| US8188235B2 (en) * | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
| JP6051049B2 (ja) | 2010-05-28 | 2016-12-21 | 中外製薬株式会社 | 抗腫瘍ｔ細胞応答増強剤 |
| WO2011149046A1 (ja) | 2010-05-28 | 2011-12-01 | 独立行政法人国立がん研究センター | 膵癌治療剤 |
| KR20220070586A (ko) | 2010-11-08 | 2022-05-31 | 제넨테크, 인크. | 피하 투여용 항―ｉｌ―6 수용체 항체 |
| WO2014200018A1 (ja) | 2013-06-11 | 2014-12-18 | 独立行政法人 国立精神・神経医療研究センター | 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法 |
| EP2898896A1 (en) | 2014-01-22 | 2015-07-29 | Université Pierre et Marie Curie (Paris 6) | Agents for use in the treatment of retinal inflammation |
| TWI805046B (zh) | 2015-02-27 | 2023-06-11 | 日商中外製藥股份有限公司 | Il-6受體抗體用於製備醫藥組成物的用途 |
| US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
| US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
| WO2019151418A1 (ja) | 2018-01-31 | 2019-08-08 | 元一 加藤 | Ｉｌ－６阻害剤を含有する喘息の治療剤 |
| CN114072173A (zh) | 2019-04-17 | 2022-02-18 | 国立大学法人广岛大学 | 以联合施用il-6抑制剂和ccr2抑制剂为特征的泌尿系统癌症治疗剂 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0672144A1 (en) * | 1992-10-20 | 1995-09-20 | Chiron Corporation | Interleukin-6 receptor antagonists |
| IT1263022B (it) * | 1992-11-06 | 1996-07-23 | Angeletti P Ist Richerche Bio | Interleuchina-6 mutante con attivita' biologica migliorata rispetto all'interleuchina-6 selvatica. |
-
1994
- 1994-12-14 IT ITRM940805A patent/IT1274782B/it active IP Right Grant
-
1995
- 1995-12-13 DK DK95940409T patent/DK0745094T3/da active
- 1995-12-13 AU AU41871/96A patent/AU702783B2/en not_active Ceased
- 1995-12-13 ES ES95940409T patent/ES2192585T3/es not_active Expired - Lifetime
- 1995-12-13 DE DE69529973T patent/DE69529973T2/de not_active Expired - Fee Related
- 1995-12-13 PT PT95940409T patent/PT745094E/pt unknown
- 1995-12-13 JP JP51856296A patent/JP3206919B2/ja not_active Expired - Fee Related
- 1995-12-13 US US08/693,182 patent/US5849283A/en not_active Expired - Fee Related
- 1995-12-13 WO PCT/IT1995/000216 patent/WO1996018648A1/en not_active Ceased
- 1995-12-13 CA CA002177838A patent/CA2177838A1/en not_active Abandoned
- 1995-12-13 EP EP95940409A patent/EP0745094B1/en not_active Expired - Lifetime
- 1995-12-13 CN CN95191575A patent/CN1070866C/zh not_active Expired - Fee Related
- 1995-12-13 AT AT95940409T patent/ATE234864T1/de not_active IP Right Cessation
-
1998
- 1998-01-16 US US09/008,482 patent/US5914106A/en not_active Expired - Fee Related
-
2001
- 2001-04-24 JP JP2001125516A patent/JP3286310B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0745094A1 (en) | 1996-12-04 |
| CN1140456A (zh) | 1997-01-15 |
| ITRM940805A1 (it) | 1996-06-14 |
| JPH09502460A (ja) | 1997-03-11 |
| CA2177838A1 (en) | 1996-06-15 |
| AU702783B2 (en) | 1999-03-04 |
| WO1996018648A1 (en) | 1996-06-20 |
| JP2001354698A (ja) | 2001-12-25 |
| ITRM940805A0 (it) | 1994-12-14 |
| ATE234864T1 (de) | 2003-04-15 |
| US5914106A (en) | 1999-06-22 |
| ES2192585T3 (es) | 2003-10-16 |
| US5849283A (en) | 1998-12-15 |
| AU4187196A (en) | 1996-07-03 |
| JP3206919B2 (ja) | 2001-09-10 |
| JP3286310B2 (ja) | 2002-05-27 |
| DE69529973T2 (de) | 2003-12-04 |
| HK1011032A1 (en) | 1999-07-02 |
| DK0745094T3 (da) | 2003-06-10 |
| EP0745094B1 (en) | 2003-03-19 |
| DE69529973D1 (de) | 2003-04-24 |
| CN1070866C (zh) | 2001-09-12 |
| PT745094E (pt) | 2003-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IT1274782B (it) | Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130 | |
| NO20055773L (no) | Immunoglobin kimeriske monomere-dimere hybrider | |
| HU9503826D0 (en) | Heterocycles useful as neurokinin antagonists | |
| DE69519748D1 (de) | Aus den vorstufen des mage tumor-abstossungsantigen abstammende einzelne peptede, die hla-a2 moleküle komplexieren | |
| DE69636720D1 (de) | Dem fibroblasten wachstumsfaktor homologer faktor-1(fhf-1) und methoden zu seiner verwendung | |
| ES2063834T3 (es) | Tgf-beta 1/beta 2: un nuevo factor del crecimiento-beta transformante quimerico. | |
| IT1261787B (it) | Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130. | |
| ATE178072T1 (de) | Neuartige polypeptide und ihre verwendung | |
| EA199800230A1 (ru) | Тетрагидрохинолины в качестве антагонистов nmda (n-метил-d-аспарагиновой кислоты) | |
| GB2399819A (en) | Method of transducing es cells | |
| BG97042A (bg) | Метод за получаване на растения,резистентни към атаките на sсlеrотiniа sсlеrотiоruм,чрез внасяне на ген,кодиращ оксалатоксидаза | |
| Leong et al. | Cloning and expression of the cDNA for bovine granulocyte-macrophage colony-stimulating factor | |
| EP0220063A3 (en) | Anti-human interleukin 1 antibody, method for the production thereof and use of the same | |
| ES8207511A1 (es) | Un procedimiento para la preparacion de nuevos peptidos. | |
| DK0876610T3 (da) | Fremgangsmåde og anvendelse af polypeptid i sædcelle-æg-binding til at foröge eller mindske fertilitet | |
| ATE145939T1 (de) | Mitogen für die glatte muskulatur und dessen kodierende dns | |
| DE60138885D1 (de) | Polypeptide mit aktivität der stimulierung von neutrophilen | |
| YOSHIDA et al. | Composition of Organic acids in ethanolic extracts of wild mushrooms | |
| Fitch et al. | Multiple lymphokine activities are secreted by a cloned murine T helper cell | |
| DK0891376T3 (da) | Antifungale peptider fra Scleroderma texense | |
| Altman et al. | Construction of T-cell hybridomas secreting distinct antigen-nonspecific lymphokines | |
| DE1676238U (de) | Handgriff zum tragen von kranzen bei der beerdigung. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 0001 | Granted |